Skip to main content

Table 1 Summary of patients’ clinical and demographic data

From: An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

ID Sex Age Diagnosis Infective diagnosis APACHE II Score1 CrCl2 Duration CVVHDF (days)
P1 M 57 Cirrhosis of liver, sepsis, ARF Pseudomonas aeruginosa 39 10 7
P2 F 68 Colonic obstruction, post-op ARF, sepsis Pseudomonas aeruginosa 28 8 14
P3 M 59 ALL with neutropenic sepsis and ARF Empiric cover for sepsis 24 5 10
P4 M 63 Ruptured abdominal aortic aneurysm repair with post-op ARF and sepsis Acinetobacter baumanni 18 5 13
P5 F 70 Pneumonia, ARDS Klebsiella pneumoniae 24 2 11
Mean   63.4   - 26.6 6 11
  1. 1 Initial/ICU admission value.
  2. 2 Creatinine clearance value on day 1 of CVVHDF, prior to commencing CVVHDF therapy. Units = ml/min; estimated using the method of Jelliffe and Jelliffe.
  3. ARF = Acute renal failure.
  4. ALL = Acute lymphocytic leukaemia.
  5. ARDS = Acute Respiratory Distress Syndrome.